| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/10/2004 | WO2004047925A2 Therapeutic oxidation catalysts |
| 06/10/2004 | WO2004047872A2 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 06/10/2004 | WO2004047868A1 Remedy for glaucoma containing lim kinase inhibitory compound as active ingredient |
| 06/10/2004 | WO2004047867A1 Colon cancer metastasis inhibitor |
| 06/10/2004 | WO2004047866A2 Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| 06/10/2004 | WO2004047856A1 Cancer metastasis inhibitor |
| 06/10/2004 | WO2004047848A1 New use of dextran sulfate |
| 06/10/2004 | WO2004047847A1 Efficient method for producing compositions enriched in total phenols |
| 06/10/2004 | WO2004047846A1 Oil/glycyrrhizin-containing surfactant phase type gel composition |
| 06/10/2004 | WO2004047845A1 CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH β2 ADRENERGIC AGONISTS |
| 06/10/2004 | WO2004047844A1 Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
| 06/10/2004 | WO2004047843A1 Method of treatment of transplant rejection |
| 06/10/2004 | WO2004047841A1 Treatment of headache with antipsychotics delivered by inhalation |
| 06/10/2004 | WO2004047839A1 High concentration formulations of opioids and opioid derivatives |
| 06/10/2004 | WO2004047837A2 Beta-blockers having antioxidant and nitric oxide-donor activity |
| 06/10/2004 | WO2004047836A1 Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| 06/10/2004 | WO2004047835A1 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation |
| 06/10/2004 | WO2004047834A1 Formulation and manufacturing process of solubilized aceclofenac soft capsules |
| 06/10/2004 | WO2004047833A2 Anthranilic acid amides and the derivatives thereof as cosmetic and pharmaceutical agents |
| 06/10/2004 | WO2004047832A1 Agent having a destructive effect on malignant tumors and method for the production thereof |
| 06/10/2004 | WO2004047831A2 Use of a pparalpha agonist and metformin for decreasing the serum triglycerides |
| 06/10/2004 | WO2004047830A2 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction |
| 06/10/2004 | WO2004047829A1 New synergistic combination comprising roflumilast and formoterol |
| 06/10/2004 | WO2004047828A1 Synergistic combination compresing roflumilas and (r.r) -formoterol |
| 06/10/2004 | WO2004047827A1 Method for promoting nail growth using thyromimetic compounds |
| 06/10/2004 | WO2004047826A1 Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| 06/10/2004 | WO2004047825A1 Use of diamide derivatives for inhibiting chronic tissue transplant rejection |
| 06/10/2004 | WO2004047824A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | WO2004047823A1 Combination of selected analgesics and cox-ii inhibitors |
| 06/10/2004 | WO2004047822A1 Hydroxypropylmethylcellulose capsule preparation having teprenone encapsulated therein |
| 06/10/2004 | WO2004047821A1 Methods for preventing phototoxic damage during photodynamic therapy |
| 06/10/2004 | WO2004047820A1 Warm poultice |
| 06/10/2004 | WO2004047819A2 Composition and its use for treating neuropathic sensory loss |
| 06/10/2004 | WO2004047818A2 USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS |
| 06/10/2004 | WO2004047817A1 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| 06/10/2004 | WO2004047816A1 Selective cyclooxygenase-2 inhibitor patch |
| 06/10/2004 | WO2004047815A1 Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor, e.g. parecoxib and valdecoxib |
| 06/10/2004 | WO2004047814A1 Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor, e.g. parecoxib, valdecoxib and benzopyran derivatives |
| 06/10/2004 | WO2004047811A1 Controlled release formulation of tamsulosin or pharmaceutically acceptable salts thereof for treatment of the signs and symptoms of benign prostatic hyperplasia |
| 06/10/2004 | WO2004047809A1 Stable pharmaceutical compositions without a stabilizer |
| 06/10/2004 | WO2004047808A1 Pharmaceutical compositions comprising amoxicillin and clavulanic acid |
| 06/10/2004 | WO2004047804A1 Emulsion of perfluororganic compounds exhibiting gas-transport properties, a surface-active agent for said emulsion and method for the production thereof. |
| 06/10/2004 | WO2004047803A1 An injection of animal remedy including closantel or closantel sodium |
| 06/10/2004 | WO2004047802A2 Liposomal formulations |
| 06/10/2004 | WO2004047801A2 Method of drug loading in liposomes by gradient |
| 06/10/2004 | WO2004047800A2 Method of drug loading in liposomes by gradient |
| 06/10/2004 | WO2004047798A2 Formulations of finasteride |
| 06/10/2004 | WO2004047796A2 Pulverulent formulation for inhalation containing tiotropium |
| 06/10/2004 | WO2004047795A2 Cutaneous application of flupirtine |
| 06/10/2004 | WO2004047778A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 06/10/2004 | WO2004047766A2 Treatment for sma disease |
| 06/10/2004 | WO2004047765A2 Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass |
| 06/10/2004 | WO2004047760A2 Novel chemical compounds |
| 06/10/2004 | WO2004047756A2 Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
| 06/10/2004 | WO2004047755A2 Fused bicyclic nitrogen-containing heterocycles |
| 06/10/2004 | WO2004047752A2 Pharmaceutical formulations of celcoxib |
| 06/10/2004 | WO2004047749A2 Purinergic modulation of smell |
| 06/10/2004 | WO2004047738A2 Arylcyclopropylcarboxylic amides as potassium channel openers |
| 06/10/2004 | WO2004047737A2 Nucleotide based medicament and method of use for treatment of conditions in humans |
| 06/10/2004 | WO2004047734A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 06/10/2004 | WO2004047732A2 Tocopherol and tocotrienol medicaments |
| 06/10/2004 | WO2004047730A2 Compounds for inhibition of hiv infection by blocking hiv entry |
| 06/10/2004 | WO2004047729A2 Composition for the prevention and treatment of inflammation of the ear |
| 06/10/2004 | WO2004047727A2 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | WO2004047726A2 Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
| 06/10/2004 | WO2004047725A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/10/2004 | WO2004047719A2 Use of iminosugar derivatives to inhibit ion channel activity |
| 06/10/2004 | WO2004047718A2 Process for manufacturing sustained release microbeads containing venlafaxine hci |
| 06/10/2004 | WO2004047713A2 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 06/10/2004 | WO2004047673A2 Treatment of liver disease with active vitamin d compounds |
| 06/10/2004 | WO2004047566A1 Nutritional compositions |
| 06/10/2004 | WO2004047565A1 Agent for foods, drinks or medical uses containing body temperature-elevating amino acid |
| 06/10/2004 | WO2004047564A1 Novel pharmaceutical compositions in particular for preventing cardiovascular pathologies |
| 06/10/2004 | WO2004037843A3 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
| 06/10/2004 | WO2004035030A3 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 06/10/2004 | WO2004033484A3 Use of stable glutamine derivatives to improve drug absorption |
| 06/10/2004 | WO2004032914A3 Use of a propargyl alcohol enantiomer for the treatment of dermatological disorders |
| 06/10/2004 | WO2004032905A8 Gabapentin tablets and methods for their preparation |
| 06/10/2004 | WO2004030678A8 Polymer compositions containing bioactive agents and methods for their use |
| 06/10/2004 | WO2004030671A3 Use of 4-amino-quinazolines as anti cancer agents |
| 06/10/2004 | WO2004030660A3 Compositions for treatment of prostate and other cancers |
| 06/10/2004 | WO2004030440A3 Synthesis of oligomeric epicatechin and catechin-derived procyanidins |
| 06/10/2004 | WO2004028461A3 Antiseptic solutions containing silver chelated with polypectate and edta |
| 06/10/2004 | WO2004026267A3 Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them |
| 06/10/2004 | WO2004026262A3 Abuse-resistant pharmaceutical compositions |
| 06/10/2004 | WO2004026241A3 Multistage formulation containing a biguanide and thiazolidindione derivatives |
| 06/10/2004 | WO2004024132A3 Use of no-signal cascade modulators and pharmaceutical composition |
| 06/10/2004 | WO2004024061A3 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| 06/10/2004 | WO2004023340A8 Non-psychotropic cannabinoids for prevention of cognitive impairment |
| 06/10/2004 | WO2004022569A9 Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 06/10/2004 | WO2004022000A3 Antibiotic microspheres for treatment of infections and osteomyelitis |
| 06/10/2004 | WO2004021987A3 Treatment of rheumatoid arthritis by inhibition of pde4 |
| 06/10/2004 | WO2004020468A3 Interferon beta-like molecules for treatment of cancer |
| 06/10/2004 | WO2004019891A3 Methods and compostions for immune tolerance |
| 06/10/2004 | WO2004017810A3 Tumor specific oligosaccharide epitopes and use thereof |
| 06/10/2004 | WO2004016578A3 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 06/10/2004 | WO2004011647A8 Modified small interfering rna molecules and methods of use |
| 06/10/2004 | WO2004010928A3 Steroid modulators in the treatment of peripheral nerve sheath tumors |
| 06/10/2004 | WO2004010924A3 Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof |
| 06/10/2004 | WO2004009543A8 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors |